XENT News and Press, Intersect ENT Inc. From 05/08/20

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30 p.m. ET on Monday, May 11, 2020. ...

Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference. The fireside chat will take place on Thursday, May 14, 2020 at 2:20 p.m. EDT. To access the webcast, go to t...

Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release first quarter 2020 financial results on May 11, 2020. The Company expects to issue the release at approximately 7:30 a....

Amgen (NASDAQ: AMGN ) initiated with Neutral rating at Guggenheim. More news on: Amgen Inc., Interpace Biosciences, Inc., Intersect ENT, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

On a preliminary basis , Intersect ENT (NASDAQ: XENT ) expects Q1 sales of $19.5M - 19.8M, down 26% (midpoint) from $26.7M a year ago and down 26% from consensus of $26.5M. More news on: Intersect ENT, Inc., Healthcare stocks news, Earnings news and commentary, , Stocks on the move, R...

- Preliminary Unaudited First Quarter 2020 Revenue Expected to be $19.5 to $19.8 Million - - Company Withdraws Full Year 2020 Guidance - Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today annou...

Quick Take Lyra Therapeutics ( LYRA ) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of treatment candidates for chronic rhinosinusitis patients. LYRA is in Phase 2 trials for its lead cand...

Image source: The Motley Fool. Intersect ENT   (NASDAQ: XENT) Q4 2019 Earnings Call Feb 24, 2020 , 8:00 a.m. ET Operator Continue reading

Intersect ENT (XENT) Q4 2019 Earnings Conference Call February 24, 2020 08:00 ET Company Participants Randy Meier - Executive Vice President and Chief Financial Officer Tom West - President and Chief Executive Officer Conference Call Participants Robbie Marcus - JPMorgan Bo...

Intersect ENT (NASDAQ: XENT ): Q4 GAAP EPS of -$0.25 beats by $0.10 . More news on: Intersect ENT, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...